Clinical relevance of CompEx Asthma and impact on disease trajectory: benralizumab effect
CompEx includes SevEx and AWEs, both of which are clinically relevant events, providing a more comprehensive assessment of asthma worsening than SevEx alone. AWEs are particularly important contributors to poor asthma outcomes and should not be ignored when evaluating treatments.
Authors
- Carla A. Da Silva
- Salman Siddiqui (ORCID: https://orcid.org/0000-0003-3770-7870)
- Peter B. Barker (ORCID: https://orcid.org/0000-0002-6410-7793)
- Njira Lucia Lugogo (ORCID: https://orcid.org/0000-0002-0235-7105)
- Praveen Akuthota (ORCID: https://orcid.org/0000-0001-6655-7520)
- Stefan Peterson (ORCID: https://orcid.org/0000-0001-7203-3096)
- Thomas Bengtsson (ORCID: https://orcid.org/0000-0002-9667-8873)
- Clare Bolton
Institutions
- Statistics Sweden (SE)
- University of Michigan (US)
- University of California San Diego (US)
- Lung Institute (US)
- AstraZeneca (Netherlands) (NL)
- Michigan Medicine (US)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Japan) (JP)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Finland) (FI)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (Spain) (ES)
- AstraZeneca (United States) (US)
- Imperial College London (GB)
- University of Gothenburg (SE)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2025-09-18
- DOI
- https://doi.org/10.1183/23120541.00486-2025
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.16